Motoki Yoshida

1.3k total citations
34 papers, 956 citations indexed

About

Motoki Yoshida is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Motoki Yoshida has authored 34 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 6 papers in Hepatology. Recurrent topics in Motoki Yoshida's work include Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (16 papers) and Cancer Treatment and Pharmacology (11 papers). Motoki Yoshida is often cited by papers focused on Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (16 papers) and Cancer Treatment and Pharmacology (11 papers). Motoki Yoshida collaborates with scholars based in Japan, South Korea and United States. Motoki Yoshida's co-authors include Hiroyasu Yasuda, Mutsuo Yamaya, T. Sasaki, Manabu Muto, Katsutoshi Nakayama, Atsushi Ohtsu, Masanori Asada, Narikazu Boku, Shigeaki Yoshida and Hiroshi Kubo and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Motoki Yoshida

33 papers receiving 944 citations

Peers

Motoki Yoshida

PRM

ONCOL

GASTR

SURGE

PHYSI

Thomas Cerny Switzerland

Jun Hihara Japan

Elena Ongaro Italy

Jingshan Ho Singapore

Javier Gómez United States

David Roife United States

Tsuneaki Fujiya Japan

Hogara Nishisaki Japan

Thomas Cerny Switzerland

Motoki Yoshida

443 ×0.9

PRM

508 ×1.5

ONCOL

68 ×0.4

GASTR

182 ×1.1

SURGE

52 ×0.4

PHYSI

Citations per year, relative to Motoki Yoshida Motoki Yoshida (= 1×) peers Thomas Cerny

Countries citing papers authored by Motoki Yoshida

Since Specialization

Citations

This map shows the geographic impact of Motoki Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motoki Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motoki Yoshida more than expected).

Fields of papers citing papers by Motoki Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motoki Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motoki Yoshida. The network helps show where Motoki Yoshida may publish in the future.

Co-authorship network of co-authors of Motoki Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Motoki Yoshida. A scholar is included among the top collaborators of Motoki Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motoki Yoshida. Motoki Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kodama, Hiroyuki, Motoki Yoshida, Masahiro Goto, et al.. (2021). [Regorafenib versus S-1 plus Bevacizumab for Metastatic Colorectal Cancer as Salvage Line-A Phase Ⅱ Study (OGSG1301)].. Gan to kagaku ryōhō. 48(10). 1241–1246. 1 indexed citations

Kusumoto, Tetsuya, Megumi Ishiguro, Eiji Nakatani, et al.. (2018). Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer. ESMO Open. 3(6). e000428–e000428. 10 indexed citations

Baba, Hideo, Yasuhide Yamada, Daisuke Takahari, et al.. (2017). S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open. 2(1). e000135–e000135. 15 indexed citations

Yoshida, Motoki, Akinori Takagane, Yasuhiro Miyake, et al.. (2016). A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). Oncology. 91(1). 24–30. 11 indexed citations

Hisamoto, Naoki, et al.. (2014). The C. elegans HGF/Plasminogen-like Protein SVH-1 Has Protease-Dependent and -Independent Functions. Cell Reports. 9(5). 1628–1634. 9 indexed citations

Yoshida, Motoki, Masahiro Goto, Takayuki Kii, et al.. (2013). Retrospective Study as First-Line Chemotherapy Combined Anti-VEGF Antibody with Fluoropyrimidine for Frail Patients with Unresectable or Metastatic Colorectal Cancer. Digestion. 87(1). 59–64. 13 indexed citations

Yamada, Yasuhide, Daisuke Takahari, Hiroshi Matsumoto, et al.. (2013). Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. The Lancet Oncology. 14(13). 1278–1286. 193 indexed citations

Nakamoto, Yoshihiko, Megumi Ishiguro, Motoki Yoshida, et al.. (2013). Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC).. Journal of Clinical Oncology. 31(15_suppl). 3518–3518. 6 indexed citations

Shitara, Kohei, Takashi Ura, Keitaro Matsuo, et al.. (2011). Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. European Journal of Cancer. 47(18). 2673–2680. 1 indexed citations

10.

Hamaguchi, Tetsuya, Kuniaki Shirao, Atsushi Ohtsu, et al.. (2011). A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer. 14(3). 226–233. 13 indexed citations

11.

Asada, Masanori, Motoki Yoshida, Yukimasa Hatachi, et al.. (2011). l-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells. Respiratory Physiology & Neurobiology. 180(1). 112–118. 13 indexed citations

12.

Yamaya, Mutsuo, Hidekazu Nishimura, Yukimasa Hatachi, et al.. (2010). Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. European Journal of Pharmacology. 650(1). 431–444. 30 indexed citations

13.

Shitara, Kohei, Satoshi Yuki, Motoki Yoshida, et al.. (2010). Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Investigational New Drugs. 30(2). 787–793. 14 indexed citations

14.

Asada, Masanori, Motoki Yoshida, Tomoko Suzuki, et al.. (2009). Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Research. 83(2). 191–200. 42 indexed citations

15.

Yoshida, Motoki, Katsutoshi Nakayama, Hiroyasu Yasuda, et al.. (2009). Carbocisteine inhibits oxidant‐induced apoptosis in cultured human airway epithelial cells. Respirology. 14(7). 1027–1034. 20 indexed citations

16.

Sasaki, T., Katsutoshi Nakayama, Hiroyasu Yasuda, et al.. (2009). A Randomized, Single‐Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients. Journal of the American Geriatrics Society. 57(8). 1453–1457. 63 indexed citations

17.

Yamasaki, Miyako, Satoru Ebihara, Takae Ebihara, et al.. (2007). Cough reflex and oral chemesthesis induced by capsaicin and capsiate in healthy never-smokers. PubMed. 3(1). 9–9. 9 indexed citations

18.

Miyamoto, Shin’ichi, Manabu Muto, Yasuo Hamamoto, et al.. (2002). A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointestinal Endoscopy. 55(4). 576–581. 188 indexed citations

19.

Yoshida, Motoki, Narikazu Boku, Atsushi Ohtsu, et al.. (2001). Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer. 4(3). 144–149. 14 indexed citations

20.

Tahara, Makoto, Narikazu Boku, Fumio Nagashima, et al.. (2001). Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer. 4(4). 212–218. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Cerny Breakdown of academic impact, for papers by Jun Hihara Breakdown of academic impact, for papers by Elena Ongaro Breakdown of academic impact, for papers by Jingshan Ho Breakdown of academic impact, for papers by Javier Gómez Breakdown of academic impact, for papers by David Roife Breakdown of academic impact, for papers by Tsuneaki Fujiya Breakdown of academic impact, for papers by Hogara Nishisaki